Dosing Guide

MK-677 Dosage Chart & Schedule Guide.

MK-677 (Ibutamoren) is a GH secretagogue that stimulates sustained GH and IGF-1 production by mimicking ghrelin. It was designed as an orally active compound, and every human trial has dosed it by mouth; a single daily dose holds IGF-1 elevated for roughly 24 hours.

⏱️
Half-life~4–6 h (dogs) · IGF-1 up 24 h+
💊
RouteOral capsule or liquid
🕗
Best timingSame hour daily · AM in trials
🌡️
StorageCapsules dry · Liquid chilled
The short answer

25 mg once daily by mouth, at the same hour every day, is the dose used in essentially every human trial. 10 mg for the first two weeks, 12.5 mg as the step down. 25 mg is the ceiling.

Dosage Protocols

Every dose below is one capsule by mouth, once a day, at the same hour. Dosing a liquid instead? Use the calculator. 25 mg is the trial dose; 10 mg is the two-week on-ramp.

Starter
10 mgonce daily, oral · 1 × 10 mg capsule
FrequencyEvery day
Weekly total70 mg/week
Cycle length2 weeks, then reassess

A real study dose, not a token one, and two weeks on it tells you how you respond.

Why this dose+

In GH-deficient adults, 10 mg raised IGF-1 about 52% and 24-hour GH about 79%. That is most of the hormonal signal for well under half the dose, which makes it a cheap way to find out how your appetite, ankles and sleep behave before committing to 25 mg.

CLINICAL TRIAL DOSEStandard
25 mgonce daily, oral · 1 × 25 mg capsule
FrequencyEvery day, same time
Weekly total175 mg/week
Cycle lengthContinuous · 12–24 months

The dose used in essentially every human trial of MK-677, taken at the same hour each day.

Why this dose+

It carried the 2-year Nass trial, the 563-patient Alzheimer's trial, the 8-week obese-male trial and the diet-catabolism study. In older adults it restored IGF-1 to young-adult range, and it showed no loss of effect out to 24 months of continuous dosing.

Reduced
12.5 mgonce daily, oral · ½ × 25 mg capsule
FrequencyEvery day
Weekly total87.5 mg/week
Cycle lengthOngoing

The step down from 25 mg: most of the IGF-1 signal survives halving the trial dose.

Why this dose+

No trial tested 12.5 mg directly, but the dose-response curve is steep at the bottom and flat at the top, so half the trial dose keeps most of the response. This is where to land if 25 mg is more than you want to carry.

MK-677 isn't a peptide, and that's why it behaves nothing like one
  • Ibutamoren is a spiropiperidine small molecule, not a chain of amino acids.
  • No vial, no bacteriostatic water, no reconstitution math, no syringe units: you swallow a capsule.
  • An injected secretagogue fires a GH pulse that fades in a couple of hours, so those protocols stack two or three shots a day.
  • MK-677 holds IGF-1 elevated across the entire 24-hour dosing interval, which is why once daily is enough.
50 mg does not give you double what 25 mg gives you
  • In GH-deficient adults, 10 mg raised IGF-1 by 52% and 24-hour mean GH by 79%.
  • Five times that dose, 50 mg, raised IGF-1 to 79% and GH to just 82%.
  • At the bottom end 2 mg barely moved IGF-1; 25 mg restored it to young-adult range in older adults.
  • The useful window is narrow, and 25 mg sits at the top of it.

Weekly Schedule

One capsule a day, seven days a week, at whichever hour you can actually keep. No human trial used a break.

Starter: 10 mg daily
M
T
W
T
F
S
S
Standard: 25 mg daily
M
T
W
T
F
S
S
Reduced: 12.5 mg daily
M
T
W
T
F
S
S
Dose taken: every day, no rest days

MK-677 has no off days at any tier: every human trial dosed it daily, and IGF-1 sits elevated across the full 24-hour interval. Missed a dose? Take it if it is still the same day, otherwise skip it rather than doubling up. In the 2-year trial it took roughly a month off the drug for IGF-1 to fall back to baseline.

MK-677 Reconstitution Calculator

A 25 mg capsule is a 25 mg dose, so this is only for the liquid and lyophilised research preparations: enter the strength, the volume you added and your target dose, and it returns the amount to draw.

mg

Double-click a preset to edit it

mL

Double-click a preset to edit it

mg

Double-click a preset to edit it

Your syringe

Standard insulin syringe

Concentration

12.50 mg/mL

1 unit = 125 mcg

Draw volume

0.800 mL

= 10.00 mg ÷ 12.50 mg/mL

Units to draw (1 mL syringe)

80.0 units

1 mL Syringe

80.0 IU
020406080100 IU

What to Expect

Sleep and appetite move within a week, IGF-1 peaks inside a month, and body composition takes a season. The metabolic cost arrives on the same schedule.

Nights 1–7Sleep deepens, appetite arrives

The fastest and most reliable change. Seven nights of 25 mg at bedtime increased stage IV (deep) sleep by about 50% and REM by over 20% in healthy young men, with episodes of disturbed sleep falling from 42% on placebo to 8%. Hunger usually shows up in the same window: 67% of trial subjects reported increased appetite versus 36% on placebo. Vivid dreams are common and expected.

Week 1–2IGF-1 climbs, water comes on

IGF-1 rises 40–52% above baseline on 25 mg and resting metabolic rate measurably increases. This is also when the puffiness appears (mild transient edema in 44% of subjects, transient muscle aches in 33%) and when glucose handling starts shifting quietly. In obese men, oral glucose tolerance was already impaired at two weeks while fasting glucose and insulin still read as normal.

Week 4–6Peak hormonal effect

IGF-1 plateaus near its ceiling. In healthy older adults, daily 25 mg lifted IGF-1 to roughly 265 µg/L, squarely in the young-adult range, and far above anything a 2 mg dose managed. The 563-patient trial measured a 60% rise at six weeks. Scale weight is up by now, and a good share of it is water and food volume rather than tissue.

Month 2–3Lean mass moves, appetite settles

Fat-free mass is up 1.1 kg at 12 months versus a 0.5 kg loss on placebo, with roughly half the gain in the limbs. In obese men at eight weeks, fat-free mass rose while total and visceral fat did not change. Appetite returned to normal within three months in about half of subjects. That extra lean mass produced no better strength or stair-climbing times in the 2-year trial.

Month 6–24No burnout, but the glucose bill arrives

MK-677 does not stop working. IGF-1 was still 1.53× baseline at 24 months of continuous dosing, with no sign of receptor desensitisation. The trade-off is that the metabolic drift is equally durable: +5 mg/dL fasting glucose and +0.2% HbA1c at 12 months, 8 of 43 subjects crossing an HbA1c of 6%, measurably lower insulin sensitivity, and a small unfavourable shift in femoral-neck bone density versus placebo.

Coming off: Trial subjects crossed from MK-677 to placebo were back at pretreatment IGF-1 within a month, and the water weight left with it, so the scale drops a few pounds in the first fortnight off. Lean tissue answers to training and protein rather than to the capsule.

Feeling Something? Check Here

🟢 Normal: keep going
  • Sharp increase in hunger, strongest in the first weeks (67% of subjects vs 36% on placebo).
  • Hunger back to normal within 3 months in about half of subjects.
  • Noticeably deeper sleep and vivid dreams.
  • Mild puffiness in hands, ankles or face early on (44%, usually transient).
  • Transient muscle aches (33%).
  • 2–3 kg on the scale in month one, much of it water and food volume.
  • Feeling warmer or sweating more.
  • Slightly lower LDL cholesterol.
🟡 Talk to your prescriber
  • Swelling that keeps worsening past 4–6 weeks, or that pits when you press it.
  • Fasting glucose creeping over 100 mg/dL, or HbA1c over 5.7% (trial average was +5 mg/dL and +0.2% at 12 months).
  • New numbness or tingling in the fingers, especially at night.
  • Persistent daytime grogginess: try shifting the dose to the morning.
  • Joint pain that limits training.
  • Blood pressure trending upward.
  • Weight gain that is clearly fat rather than tissue.
  • For any of these: drop to 12.5 mg and recheck fasting glucose, fasting insulin and HbA1c before going back up.
🔴 Stop and call a doctor
  • Breathlessness lying flat, waking up short of breath, or rapid weight gain with swollen legs (heart-failure signs).
  • A 25 mg trial in frail hip-fracture patients was stopped early after congestive heart failure in 6.5% versus 1.7% on placebo.
  • Chest pain or pressure.
  • Fasting glucose above 126 mg/dL, or raging thirst, frequent urination and blurred vision.
  • Severe persistent headache with vision changes.
  • Any new lump, or a mole or mass growing quickly.
Do not use MK-677 if any of these apply
  • Active, suspected or previously treated cancer: IGF-1 is a growth signal and every trial excluded malignancy.
  • Type 1 or type 2 diabetes, or prediabetes that is not well controlled: the pivotal trial excluded diabetics outright.
  • Existing heart failure, or frail/elderly recovery from acute fracture or illness: 25 mg/day produced congestive heart failure in 6.5% versus 1.7% on placebo, and that trial was halted early.
  • Untreated or poorly controlled hypertension.
  • Pregnancy, breastfeeding, or actively trying to conceive.
  • Under 18 or with open growth plates, outside paediatric endocrinology supervision.
  • Acromegaly or an active pituitary tumour.
  • Drug-tested athletes and US service members: WADA-prohibited at all times, in and out of competition, and on the DoD prohibited ingredient list.
  • Anyone unwilling to run baseline and follow-up fasting glucose and HbA1c.

FAQ

Is MK-677 actually a peptide?+

No. Ibutamoren mesylate is a spiropiperidine small molecule designed by Merck in the mid-1990s specifically to survive digestion; it is not a chain of amino acids. It gets shelved with peptides because it activates the same receptor as ghrelin (GHS-R1a), the target GHRP-6, hexarelin and ipamorelin also hit. Practically, that means no vial, no bacteriostatic water, no reconstitution calculation and no syringe. You swallow a capsule, once a day.

Morning or bedtime: which is right?+

Both are defensible; the important thing is picking one and staying consistent. The 2-year pivotal trial dosed 25 mg between 7 and 9 AM. The sleep study dosed at bedtime and found roughly 50% more deep sleep and over 20% more REM. Bedtime is the classic choice for sleep quality, but it is also the classic cause of morning grogginess and midnight fridge raids. If you wake up foggy or ravenous, move it to the morning; IGF-1 stays elevated across the full 24 hours either way, so you lose nothing.

Do I need to cycle it, or can I run it continuously?+

There is no evidence MK-677 desensitises. IGF-1 was still 1.53 times baseline after 24 months of uninterrupted 25 mg dosing, so the popular "8 weeks on, 4 weeks off" rule is not about receptor burnout; it is folklore borrowed from steroid protocols. The genuine reason to take breaks is metabolic: fasting glucose, HbA1c and insulin sensitivity drift the longer you stay on. Time your breaks around blood work, not around a calendar.

What blood work should I run?+

Before starting: fasting glucose, HbA1c, fasting insulin (for HOMA-IR), IGF-1, a lipid panel and blood pressure. Recheck at 8–12 weeks, then every 3–6 months. One finding is worth internalising: in obese men, oral glucose tolerance was already impaired at two weeks while fasting glucose and fasting insulin still looked completely normal. A clean fasting glucose does not mean nothing is happening. If you can, add an OGTT or at least track fasting insulin, not just glucose.

Will I keep the muscle after I stop?+

The hormonal signal disappears fast; subjects crossed to placebo were back at pretreatment IGF-1 within about a month, and the water weight goes with it, which is why the scale can drop several pounds in two weeks. Actual lean tissue is a different matter: muscle responds to training and protein, not to the capsule, so what you built is yours to keep if the training stimulus stays. Worth knowing, though, that in the 2-year trial the 1.1 kg of extra fat-free mass produced no measurable improvement in strength or stair-climbing, so do not expect the compound itself to have made you stronger.

Does MK-677 burn fat?+

Not reliably on its own. In obese men on 25 mg for eight weeks, total and visceral fat were unchanged. In older adults at 12 months, fat mass rose slightly more on MK-677 than on placebo and limb fat rose significantly, with body weight up 2.7 kg, because appetite went up 67%. If you eat into a surplus, you will gain fat. Where it genuinely shines is protecting lean tissue in a deficit: during severe calorie restriction, 25 mg flipped nitrogen balance from −1.48 g/day on placebo to +0.31 g/day, meaning subjects stopped losing lean mass while still dieting.

Is it legal, and will it show up on a drug test?+

MK-677 has never been approved by the FDA for any use and is not a lawful dietary-supplement ingredient. The FDA has issued warning letters to companies selling it (including one in December 2025 over a children's growth product containing undeclared ibutamoren), and it appears on the DoD Prohibited Dietary Supplement Ingredients List. WADA prohibits it at all times, in and out of competition. Standard workplace drug panels do not screen for it; anti-doping panels do, and urinary metabolite methods published since 2024 have extended the detection window.

Can I stack it with a GLP-1, or use it while cutting?+

Mechanistically they pull in opposite directions on appetite: MK-677 is a ghrelin-receptor agonist that turns hunger up, GLP-1s turn it down, and some people pair them deliberately to blunt the appetite spike while preserving lean mass in a deficit. No trial has tested that combination, and both nudge glucose metabolism, so treat it as an experiment and monitor labs closely. What is trial-backed is MK-677's nitrogen-sparing effect during calorie restriction; that part is real and is the single best-supported reason to use it while cutting.

Sources

Every dose, percentage and adverse-event rate on this page comes from the trials and regulatory records below.

Disclaimer: This content is for informational and research purposes only and is not medical advice. MK-677 (ibutamoren) has never been approved by the FDA for any use, is not a lawful dietary-supplement ingredient, and is prohibited by WADA at all times. Every protocol described here is off-label and unapproved. Always consult a qualified healthcare professional before starting any compound. PeptideDeck is not responsible for individual use.

Claim 50% Off